PsiOxus raises £25m to progress 'armed' cancer vaccines
This article was originally published in Scrip
Executive Summary
PsiOxus Therapeutics has closed a series C financing of £25m led by founding investor Imperial Innovations to fund its oncolytic immuno-oncology pipeline.